Full text is available at the source.
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Developing Powerful Weight Loss Drugs That Target Multiple Body Systems in One Molecule
AI simplified
Abstract
More than 2.5 billion adults worldwide are affected by obesity and type 2 diabetes mellitus (T2DM).
- Unimolecular polypharmacology designs single molecules to target multiple receptors or pathways.
- Tirzepatide and retatrutide have shown superior efficacy in managing obesity and T2DM compared to traditional single agonists.
- Tirzepatide has been noted for its effectiveness in weight loss and glycemic control, along with additional cardiovascular and renal benefits.
- Challenges with these therapies include gastrointestinal side effects, patient compliance issues, and weight rebound after treatment cessation.
- The development of these agents highlights the potential of unimolecular polypharmacology in treating metabolic diseases.
AI simplified